Recro Pharma (REPH) PT Lowered to $9 at Oppenheimer Following IV Meloxicam CRL
Tweet Send to a Friend
Oppenheimer analyst Leland Gershell lowered the price target on Recro Pharma (NASDAQ: REPH) to $9.00 (from $19.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
